These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 24141627)

  • 1. Use of the proton pump inhibitor pantoprazole to modify the distribution and activity of doxorubicin: a potential strategy to improve the therapy of solid tumors.
    Patel KJ; Lee C; Tan Q; Tannock IF
    Clin Cancer Res; 2013 Dec; 19(24):6766-76. PubMed ID: 24141627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of the proton pump inhibitor lansoprazole on distribution and activity of doxorubicin in solid tumors.
    Yu M; Lee C; Wang M; Tannock IF
    Cancer Sci; 2015 Oct; 106(10):1438-47. PubMed ID: 26212113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs.
    Luciani F; Spada M; De Milito A; Molinari A; Rivoltini L; Montinaro A; Marra M; Lugini L; Logozzi M; Lozupone F; Federici C; Iessi E; Parmiani G; Arancia G; Belardelli F; Fais S
    J Natl Cancer Inst; 2004 Nov; 96(22):1702-13. PubMed ID: 15547183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin.
    Brana I; Ocana A; Chen EX; Razak AR; Haines C; Lee C; Douglas S; Wang L; Siu LL; Tannock IF; Bedard PL
    Invest New Drugs; 2014 Dec; 32(6):1269-77. PubMed ID: 25213162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Up-regulation of autophagy is a mechanism of resistance to chemotherapy and can be inhibited by pantoprazole to increase drug sensitivity.
    Tan Q; Joshua AM; Wang M; Bristow RG; Wouters BG; Allen CJ; Tannock IF
    Cancer Chemother Pharmacol; 2017 May; 79(5):959-969. PubMed ID: 28378028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors.
    Primeau AJ; Rendon A; Hedley D; Lilge L; Tannock IF
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8782-8. PubMed ID: 16361566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of pantoprazole to enhance activity of docetaxel against human tumour xenografts by inhibiting autophagy.
    Tan Q; Joshua AM; Saggar JK; Yu M; Wang M; Kanga N; Zhang JY; Chen X; Wouters BG; Tannock IF
    Br J Cancer; 2015 Mar; 112(5):832-40. PubMed ID: 25647012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pantoprazole: a proton pump inhibitor with oral and intravenous formulations.
    Devault KR
    Expert Rev Gastroenterol Hepatol; 2007 Dec; 1(2):197-205. PubMed ID: 19072410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LASS2 enhances chemosensitivity of breast cancer by counteracting acidic tumor microenvironment through inhibiting activity of V-ATPase proton pump.
    Fan S; Niu Y; Tan N; Wu Z; Wang Y; You H; Ke R; Song J; Shen Q; Wang W; Yao G; Shu H; Lin H; Yao M; Zhang Z; Gu J; Qin W
    Oncogene; 2013 Mar; 32(13):1682-90. PubMed ID: 22580606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor acidity, chemoresistance and proton pump inhibitors.
    De Milito A; Fais S
    Future Oncol; 2005 Dec; 1(6):779-86. PubMed ID: 16556057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor.
    Lee ES; Na K; Bae YH
    J Control Release; 2005 Mar; 103(2):405-18. PubMed ID: 15763623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increasing sodium pantoprazole photostability by microencapsulation: effect of the polymer and the preparation technique.
    Raffin RP; Colomé LM; Schapoval EE; Pohlmann AR; Guterres SS
    Eur J Pharm Biopharm; 2008 Aug; 69(3):1014-8. PubMed ID: 18374552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues.
    Patel KJ; Trédan O; Tannock IF
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):127-38. PubMed ID: 23680920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomised clinical trial: twice daily esomeprazole 40 mg vs. pantoprazole 40 mg in Barrett's oesophagus for 1 year.
    de Bortoli N; Martinucci I; Piaggi P; Maltinti S; Bianchi G; Ciancia E; Gambaccini D; Lenzi F; Costa F; Leonardi G; Ricchiuti A; Mumolo MG; Bellini M; Blandizzi C; Marchi S
    Aliment Pharmacol Ther; 2011 May; 33(9):1019-27. PubMed ID: 21385192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy.
    Paliwal SR; Paliwal R; Pal HC; Saxena AK; Sharma PR; Gupta PN; Agrawal GP; Vyas SP
    Mol Pharm; 2012 Jan; 9(1):176-86. PubMed ID: 22091702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model.
    Wong HL; Rauth AM; Bendayan R; Wu XY
    Eur J Pharm Biopharm; 2007 Mar; 65(3):300-8. PubMed ID: 17156986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors.
    Vanhoefer U; Cao S; Minderman H; Toth K; Skenderis BS; Slovak ML; Rustum YM
    Clin Cancer Res; 1996 Dec; 2(12):1961-8. PubMed ID: 9816155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of p.o. or i.v. proton pump inhibitors on 72-h intragastric pH in bleeding peptic ulcer.
    Javid G; Zargar SA; U-Saif R; Khan BA; Yatoo GN; Shah AH; Gulzar GM; Sodhi JS; Khan MA
    J Gastroenterol Hepatol; 2009 Jul; 24(7):1236-43. PubMed ID: 19682194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel anthracene derivative, MHY412, induces apoptosis in doxorubicin-resistant MCF-7/Adr human breast cancer cells through cell cycle arrest and downregulation of P-glycoprotein expression.
    De U; Chun P; Choi WS; Lee BM; Kim ND; Moon HR; Jung JH; Kim HS
    Int J Oncol; 2014 Jan; 44(1):167-76. PubMed ID: 24190517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On-demand proton pump inhibitory treatment in overweight/obese patients with gastroesophageal reflux disease: are there pharmacodynamic arguments for using higher doses?
    Bruley des Varannes S; Coudsy B; Waechter S; Delemos B; Xiang J; Lococo J; Ducrotté P
    Digestion; 2013; 88(1):56-63. PubMed ID: 23880545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.